CRISPR-Based Diagnostics Market to Grow with a CAGR of 17.02% through 2030
Growing
demand for rapid and precise molecular diagnostics and increasing adoption of
CRISPR technology in point-of-care testing, is expected to
drive the Global CRISPR-Based Diagnostics Market growth in the forecast period,
2026-2030
According to
TechSci Research report, “CRISPR-Based Diagnostics Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global CRISPR-Based Diagnostics Market stood at USD 3.16 Billion in
2024 and is expected to reach USD 8.12 Billion by 2030 with a CAGR of 17.02% during
the forecast period. The
Global CRISPR-Based Diagnostics Market is evolving as a transformative segment
within the molecular diagnostics landscape, propelled by the need for
next-generation tools that enable real-time, ultra-specific detection of
pathogens and genetic anomalies. The simplicity, programmability, and
adaptability of CRISPR systems are reshaping conventional diagnostic frameworks
by offering faster turnaround times and higher sensitivity without the need for
extensive amplification or complex instrumentation. Rising consumer
expectations for rapid diagnostic results in both clinical and at-home settings
is accelerating interest in CRISPR-enabled point-of-care devices. The
increasing importance of early intervention in chronic and hereditary diseases
is prompting healthcare providers and research institutions to explore novel
CRISPR applications in routine screening and precision diagnostics.
One
of the most significant trends influencing the market is the integration of
CRISPR diagnostics into mobile and digital health ecosystems. Startups and
established biotech players are focusing on the development of
smartphone-compatible CRISPR diagnostic platforms that support remote result
interpretation and cloud-based data storage. A notable shift is also occurring
toward single-molecule detection and amplification-free workflows, reducing
sample preparation time and infrastructure needs. As diagnostics move toward a
patient-centric model, there is a rising interest in developing wearable CRISPR
sensors capable of continuous health monitoring. The transition from bench to
bedside is being expedited by innovations in reagent lyophilization, microfluidic
chip designs, and ambient-temperature test formats that offer logistical
advantages for global deployment.
Despite
these barriers, growth opportunities are abundant. Expanding use cases in
veterinary diagnostics, food safety testing, agricultural genomics, and
environmental monitoring offer new revenue streams beyond human healthcare.
Government-funded genomic surveillance programs, particularly in infectious
disease hotspots, are opening up public sector contracts for CRISPR diagnostic
kits. Emerging markets with improving laboratory infrastructure and rising
R&D investments are becoming strategic locations for both manufacturing and
end-user demand. Licensing opportunities, white-label production, and
co-development partnerships with global health agencies can accelerate
commercial rollout. As CRISPR continues to mature as a diagnostic modality, its
integration with AI, synthetic biology, and telehealth platforms presents a
compelling frontier for scalable, real-time disease detection worldwide.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global CRISPR-Based Diagnostics Market”
The Global CRISPR-Based
Diagnostics Market is segmented into product, technology, application, end user,
regional distribution, and company.
Based on the Application,
Cancer Diagnostics emerged as the fastest growing segment in the Global CRISPR-Based
Diagnostics Market during the forecast period. This is driven by the urgent need for more
precise, rapid, and accessible tools for early cancer detection and monitoring.
Traditional cancer diagnostic methods, such as biopsies and imaging, often face
limitations in sensitivity, turnaround time, and the ability to detect
early-stage malignancies. CRISPR-based diagnostics offer high specificity by
targeting cancer-associated genetic mutations, enabling the identification of
oncogenic biomarkers directly from blood, saliva, or tissue samples with
minimal processing. The ability to design CRISPR systems to detect multiple
mutations or gene fusions associated with different cancer types including
lung, colorectal, breast, and prostate cancer has expanded their application
across oncology.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
CRISPR-Based Diagnostics Market during
the forecast period. Asia-Pacific’s growing biopharmaceutical manufacturing
base and emerging startup ecosystem are supporting the commercialization of
CRISPR diagnostic technologies at a competitive cost. Regional players are
entering strategic partnerships with global diagnostics firms to co-develop and
distribute CRISPR-based assays, benefiting from technology transfer and
regulatory alignment. Regulatory bodies in countries like Japan and South Korea
are taking progressive steps to establish clear approval frameworks for
molecular diagnostics, fostering a more conducive environment for innovation.
Increasing public health surveillance initiatives and growing demand for
personalized healthcare solutions are further propelling market growth.
Moreover, rising disposable income, improving diagnostic awareness, and the
expansion of private healthcare infrastructure are enabling broader adoption of
advanced diagnostics. The region’s ability to combine low-cost manufacturing
with skilled scientific talent makes it a key hub for CRISPR technology
development.
Major
companies operating in Global CRISPR-Based Diagnostics Market are:
- Thermo
Fisher Scientific Inc.
- Integrated
DNA Technologies, Inc.
- Molbio
Diagnostics
- Horizon
Discovery
- Synthego
Corporation
- Mammoth
Biosciences
- Sherlock
Biosciences
- Caribou
Biosciences
- CrisprBits
- ToolGen
Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global CRISPR-Based Diagnostics
Market is expanding due to the increasing demand for amplification-free
molecular testing solutions that can deliver accurate, real-time results
without the need for complex laboratory infrastructure. This capability is
especially valuable for enabling decentralized testing in low-resource
settings, rural healthcare centers, and mobile diagnostic units. CRISPR-based
platforms are being rapidly adopted for field applications such as infectious
disease surveillance, agricultural biosafety, and public health monitoring,
where portability, speed, and minimal equipment are critical. Their ability to
function efficiently without thermal cyclers or trained personnel is
positioning them as essential tools in global diagnostic strategies.,”
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“CRISPR-Based Diagnostics
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Product (Enzymes, Kits and Reagents, Software and Libraries), By
Technology (Cas9, Cas12, Others), By Application (Infectious Disease
Diagnostics, Genetic Disorder Diagnostics, Cancer Diagnostics, Others), By End
User (Hospitals and Clinics Diagnostic, Laboratories, Pharmaceutical and
Biotechnology Companies, Others), By Region and Competition, 2020-2030F”,
has evaluated the future growth potential of Global CRISPR-Based Diagnostics
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global CRISPR-Based
Diagnostics Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com